Waters beats estimates on earnings and revenue as pharmaceutical segment grows
Updated
Updated · CNBC · May 5
Waters beats estimates on earnings and revenue as pharmaceutical segment grows
1 articles · Updated · CNBC · May 5
Adjusted EPS reached $2.70 versus $2.31 expected, while revenue was $1.27bn against a $1.20bn forecast; pharmaceutical sales rose 14%.
Asia was the strongest region, growing nearly 30%, led by more than 50% growth in China, with high single-digit gains in the Americas and Europe.
CEO Udit Batra said Chinese biotech is becoming a major global innovation source, with about one-third of molecules licensed by large drugmakers now coming from China.
Is China's surge in 'first-in-class' drugs a true innovation leap or a well-funded development machine?
China now approves new drugs three times faster than the U.S. Is America losing its position as the world's pharmacy?
With US restrictions tightening, how can pharma firms tap China's innovation without risking their supply chains?
In Q1 2026, Waters Corporation achieved a remarkable 91% revenue increase to $1.267 billion, driven by the early integration of BD's Biosciences and Diagnostic Solutions businesses and strong organic growth in its existing operations. The acquisition expanded Waters into molecular diagnostics and flow cytometry, boosting its total addressable market and recurring revenue base. Key divisions like Analytical Sciences and Advanced Diagnostics showed significant growth, supported by innovations such as enhancements to the Empower software platform for biologics. Confident in its integration progress and synergy plans, Waters raised its full-year financial outlook and projected continued growth, despite facing integration complexities and market headwinds.